Aclaris Therapeutics, Inc.
- ACRS
- NASDAQ
- Biotechnology
- Immunology Biotech
- Immune-Inflammatory Treatments
$3.48
Today +6.10%Quote Oct 19, 2026, 08:00 PM UTC
−36.73%over the last month
Max drawdown −42.7%From 1-month high −39.2%3 months −38.8%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions.
Where the money comes from
Q2 2026 revenue $1.6M
- License and Service$1.3M78.1%
- Contract research$356,00021.9%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
71
Market value
$512.3M
Quote Oct 19
Floor
$3.46
0.7% below price
Resistance
$3.66
5.3% above price
Price vs analyst targets
16 analysts
Lowest target
$10.00Highest target
$12.00
$10.00Highest target
$12.00
- Price $3.48
- Average target $10.75
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 209% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ACRSPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free